Literature DB >> 2529851

Human plasma fibronectin as a substrate for human urokinase.

L I Gold1, R Schwimmer, J P Quigley.   

Abstract

An early event in malignant transformation is the increased expression of proteases, such as plasminogen activator, which can degrade surrounding extracellular matrices, thereby conferring an advantage for tumour cell invasion and metastasis. The present studies provide evidence that plasma fibronectin (Fn), which is a component of the extracellular matrix, is a direct substrate for the plasminogen activator urokinase (UK). Human plasma Fn was incubated with human UK under plasminogen-free conditions. Fn cleavage was both time- and dose-dependent and was evident within 30 min. The proteolytic digestion was limited and complete within 12 h at an enzyme/substrate ratio of 1:20. Analysis of the final proteolytic digestion products demonstrated the disappearance of the native dimeric 440 kDa structure of Fn with the concomitant appearance of three proteolytic fragments of 210, 200 and 25 kDa. Since two large fragments of similar size to the 220 kDa monomeric chains of Fn were obtained following proteolysis, it is proposed that UK cleaves Fn at two sites, one towards the N-terminal and one close to the C-terminal, but N-terminal to its interchain disulphide bonds. These studies suggest that the local proteolytic digestion and release of Fn from the extracellular matrix by tumour cells possessing high levels of UK may involve the direct proteolytic breakdown of Fn by UK.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529851      PMCID: PMC1133300          DOI: 10.1042/bj2620529

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  Purification of urokinase by affinity chromatography.

Authors:  L Holmberg; B Bladh; B Astedt
Journal:  Biochim Biophys Acta       Date:  1976-08-12

2.  High-molecular-weight glycorprotein as a mediator of cellular adhesion.

Authors:  E Pearlstein; L I Gold
Journal:  Ann N Y Acad Sci       Date:  1978-06-20       Impact factor: 5.691

3.  A difference between plasma and cellular fibronectins located with monoclonal antibodies.

Authors:  B T Atherton; R O Hynes
Journal:  Cell       Date:  1981-07       Impact factor: 41.582

Review 4.  Fibronectin: current concepts of its structure and functions.

Authors:  E Ruoslahti; E Engvall; E G Hayman
Journal:  Coll Relat Res       Date:  1981

5.  Solubilization and degradation of subendothelial matrix glycoproteins and proteoglycans by metastatic tumor cells.

Authors:  R H Kramer; K G Vogel; G L Nicolson
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

6.  Proteolytically derived fragments of human plasma fibronectin and their localization within the intact molecule.

Authors:  M B Furie; D B Rifkin
Journal:  J Biol Chem       Date:  1980-04-10       Impact factor: 5.157

7.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

Authors:  L A Liotta; R H Goldfarb; R Brundage; G P Siegal; V Terranova; S Garbisa
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells.

Authors:  P A Jones; Y A DeClerck
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

Review 9.  Fibronectin: a review of its structure and biological activity.

Authors:  E Pearlstein; L I Gold; A Garcia-Pardo
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

10.  Serine enzymes released by cultured neoplastic cells.

Authors:  K Danø; E Reich
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  15 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  Secretion of urokinase and plasminogen activator inhibitor-1 by normal colonic epithelium in vitro.

Authors:  P Gibson; O Rosella; G Rosella; G Young
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

Review 3.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

4.  Integrin alpha6 cleavage: a novel modification to modulate cell migration.

Authors:  Sangita C Pawar; Manolis C Demetriou; Raymond B Nagle; G Tim Bowden; Anne E Cress
Journal:  Exp Cell Res       Date:  2007-01-17       Impact factor: 3.905

5.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

6.  Protein kinase Cε-calcineurin cosignaling downstream of toll-like receptor 4 downregulates fibrosis and induces wound healing gene expression in cardiac myofibroblasts.

Authors:  Rui F D S Mesquita; Margaret A Paul; Aida Valmaseda; Asvi Francois; Rita Jabr; Shahzia Anjum; Michael S Marber; Vishwanie Budhram-Mahadeo; Richard J Heads
Journal:  Mol Cell Biol       Date:  2013-12-02       Impact factor: 4.272

Review 7.  Serine proteases, inhibitors and receptors in renal fibrosis.

Authors:  Allison A Eddy
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

8.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.

Authors:  A P Sappino; J Huarte; J D Vassalli; D Belin
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes.

Authors:  M A Turner; J M Palefsky
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

10.  Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.

Authors:  Manolis C Demetriou; Michael E Pennington; Raymond B Nagle; Anne E Cress
Journal:  Exp Cell Res       Date:  2004-04-01       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.